CU24316B1 - Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen - Google Patents
Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienenInfo
- Publication number
- CU24316B1 CU24316B1 CUP2014000095A CU20140095A CU24316B1 CU 24316 B1 CU24316 B1 CU 24316B1 CU P2014000095 A CUP2014000095 A CU P2014000095A CU 20140095 A CU20140095 A CU 20140095A CU 24316 B1 CU24316 B1 CU 24316B1
- Authority
- CU
- Cuba
- Prior art keywords
- formula
- compounds
- preparation
- tetraisoquinolina
- phyphate
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 241000670727 Amida Species 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 abstract 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 230000006909 anti-apoptosis Effects 0.000 abstract 1
- 150000007942 carboxylates Chemical class 0.000 abstract 1
- 150000001735 carboxylic acids Chemical class 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<p>Compuestos derivados de fosfatos de 1,2,3,4- tetraisoquinolina amida fenilo de fórmula (I):</p> <p>ESPACIO PARA FORMULA</p> <p>El método de preparación comprende una reacción de Heck, entre dos compuestos, para formar otro compuesto, cuyo aldehído se oxida, se acopla peptídicamente al compuesto de fórmula (VI) formando un compuesto cuyo éster se hidroliza, forma el ácido carboxílico o carboxilato correspondiente, se convierte en un derivado de ácido, se acopla con una amina NHR3R4, reacciona con un derivado fosfato y se hidroliza o hidrogenoliza. Dichos compuestos poseen solubilidad muy superior a los compuestos de fórmula (I´), que inhiben la antiapoptosis causada por proteínas Bcl-2, por lo que son útiles contra cánceres quimio o radioresistentes, hemopatías malignas y cáncer de pulmón de células pequeñas.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1357259A FR3008979B1 (fr) | 2013-07-23 | 2013-07-23 | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20140095A7 CU20140095A7 (es) | 2016-02-29 |
| CU24316B1 true CU24316B1 (es) | 2018-02-08 |
Family
ID=50288170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2014000095A CU24316B1 (es) | 2013-07-23 | 2014-07-23 | Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen |
Country Status (48)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| FR3008976A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
| FR3008977A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| UY37316A (es) * | 2016-07-07 | 2018-01-31 | Servier Lab | Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer |
| WO2018015526A1 (en) | 2016-07-22 | 2018-01-25 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof |
| EP3487499A1 (en) * | 2016-07-22 | 2019-05-29 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof |
| WO2018158225A1 (en) | 2017-02-28 | 2018-09-07 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof |
| EA039621B1 (ru) * | 2017-06-09 | 2022-02-17 | Ле Лаборатуар Сервье | Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции |
| TWI672302B (zh) * | 2017-07-06 | 2019-09-21 | 法商施維雅藥廠 | Bcl-2抑制劑之新結晶型、其製備方法及含其之醫藥組合物 |
| FR3072679B1 (fr) * | 2017-10-25 | 2020-10-30 | Servier Lab | Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| CA3089630A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
| TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| EP4013412A1 (en) | 2019-08-12 | 2022-06-22 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| CN110606860B (zh) * | 2019-09-29 | 2021-12-10 | 上海勋和医药科技有限公司 | 一种吡啶磺酰胺磷酸酯类化合物、其制备方法及其用途 |
| EP4084778B1 (en) | 2019-12-30 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Amorphous kinase inhibitor formulations and methods of use thereof |
| EP4084779B1 (en) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| KR20230157419A (ko) * | 2021-03-12 | 2023-11-16 | 에일 테라퓨틱스 인코포레이티드 | Bcl-2 저해제로서의 테트라하이드로인돌리진-1-카복스아마이드를 갖는 화합물 |
| WO2023057394A1 (en) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003093297A2 (en) * | 2002-05-03 | 2003-11-13 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| AU2003249713A1 (en) * | 2002-07-03 | 2004-01-23 | Axys Pharmaceuticals, Inc. | 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis |
| GB0224557D0 (en) * | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| CN101356159A (zh) | 2005-12-22 | 2009-01-28 | 惠氏公司 | 经取代异喹啉-1,3(2h,4h)-二酮类、1-硫代-1,4-二氢-2h-异喹啉-3-酮类和1,4-二氢-3(2h)-异喹啉酮类以及其作为激酶抑制剂的用途 |
| US7902218B2 (en) | 2006-12-12 | 2011-03-08 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinolines as β-secretase inhibitors |
| ES2705599T3 (es) * | 2007-04-16 | 2019-03-26 | Abbvie Inc | Indoles sustituidos en la posición 7 como inhibidores de mcl-1 |
| AU2008254061B2 (en) * | 2007-05-22 | 2012-06-14 | Astellas Pharma Inc. | 1-substituted tetrahydroisoquinoline compound |
| AU2009215191A1 (en) * | 2008-02-13 | 2009-08-20 | Gilead Connecticut, Inc. | 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof |
| RU2525116C2 (ru) * | 2008-12-19 | 2014-08-10 | Дженентек, Инк. | Гетероциклические соединения и способы применения |
| TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| US20120301080A1 (en) | 2011-05-23 | 2012-11-29 | Senko Advanced Components, Inc. | True one piece housing fiber optic adapter |
| JP2015503517A (ja) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Ｂｃｌ２と結合相手の相互作用を阻害するための化合物 |
| BR112014015339A2 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos para inibição da interação de bcl2 com parceiros de ligação |
| MX2014007729A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
| JP2015503516A (ja) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Ｂｃｌ２と結合相手の相互作用を阻害するための化合物 |
| BR112014015322A2 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos e composições para inibir a interação de bcl2 com parceiros de ligação |
| CN103177906A (zh) | 2011-12-26 | 2013-06-26 | 西门子公司 | 用于中压开关设备的断路器 |
| ITPR20110103A1 (it) | 2011-12-27 | 2013-06-28 | G E A F S R L | Metodo e apparato per la sterilizzazione di una soluzione liquida mediante radio frequenza |
| US9114953B2 (en) | 2011-12-29 | 2015-08-25 | Inventio Ag | Emergency operation of elevators based on an indicated emergency condition |
| WO2013110990A2 (en) | 2012-01-24 | 2013-08-01 | Danfoss A/S | Dehumidifier |
| FR2986002B1 (fr) * | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2013
- 2013-07-23 FR FR1357259A patent/FR3008979B1/fr active Active
-
2014
- 2014-07-08 PH PH12014000194A patent/PH12014000194A1/en unknown
- 2014-07-09 SG SG10201403939WA patent/SG10201403939WA/en unknown
- 2014-07-09 AP AP2014007773A patent/AP2014007773A0/xx unknown
- 2014-07-09 JO JOP/2014/0222A patent/JO3160B1/ar active
- 2014-07-10 PE PE2014001093A patent/PE20150218A1/es active IP Right Grant
- 2014-07-10 EC ECIEPI20148757A patent/ECSP14008757A/es unknown
- 2014-07-10 MY MYPI2014701887A patent/MY173258A/en unknown
- 2014-07-10 IL IL233580A patent/IL233580B/en active IP Right Grant
- 2014-07-11 CR CR20140336A patent/CR20140336A/es unknown
- 2014-07-11 AU AU2014203808A patent/AU2014203808B2/en active Active
- 2014-07-11 UY UY35661A patent/UY35661A/es unknown
- 2014-07-11 TN TNP2014000301A patent/TN2014000301A1/fr unknown
- 2014-07-14 CA CA2856886A patent/CA2856886C/fr active Active
- 2014-07-15 DO DO2014000163A patent/DOP2014000163A/es unknown
- 2014-07-15 MA MA37213A patent/MA37213B1/fr unknown
- 2014-07-15 MD MDA20140073A patent/MD4551C1/ro not_active IP Right Cessation
- 2014-07-15 CL CL2014001865A patent/CL2014001865A1/es unknown
- 2014-07-17 SV SV2014004771A patent/SV2014004771A/es unknown
- 2014-07-17 UA UAA201408109A patent/UA119738C2/uk unknown
- 2014-07-21 GE GEAP201413528A patent/GEP201706704B/en unknown
- 2014-07-22 MX MX2014008866A patent/MX351467B/es active IP Right Grant
- 2014-07-22 WO PCT/FR2014/051887 patent/WO2015011399A1/fr active Application Filing
- 2014-07-22 HU HUE14178030A patent/HUE029616T2/en unknown
- 2014-07-22 RS RS20160693A patent/RS55098B1/sr unknown
- 2014-07-22 US US14/337,577 patent/US9115159B2/en active Active
- 2014-07-22 PL PL14178030.4T patent/PL2829545T3/pl unknown
- 2014-07-22 TW TW103125160A patent/TWI527824B/zh not_active IP Right Cessation
- 2014-07-22 BR BR102014017997A patent/BR102014017997B1/pt active IP Right Grant
- 2014-07-22 RU RU2014130129A patent/RU2617682C2/ru active
- 2014-07-22 DK DK14178030.4T patent/DK2829545T3/en active
- 2014-07-22 ES ES14178030.4T patent/ES2593417T3/es active Active
- 2014-07-22 NI NI201400080A patent/NI201400080A/es unknown
- 2014-07-22 AR ARP140102712A patent/AR097008A1/es unknown
- 2014-07-22 SA SA114350669A patent/SA114350669B1/ar unknown
- 2014-07-22 EP EP14178030.4A patent/EP2829545B1/fr active Active
- 2014-07-22 ZA ZA2014/05418A patent/ZA201405418B/en unknown
- 2014-07-22 EA EA201400754A patent/EA027444B1/ru unknown
- 2014-07-22 JP JP2014148946A patent/JP5894638B2/ja active Active
- 2014-07-22 SI SI201430059A patent/SI2829545T1/sl unknown
- 2014-07-22 ME MEP-2016-208A patent/ME02641B/me unknown
- 2014-07-22 PT PT141780304T patent/PT2829545T/pt unknown
- 2014-07-23 CU CUP2014000095A patent/CU24316B1/es unknown
- 2014-07-23 CN CN201410354089.1A patent/CN104341451B/zh active Active
- 2014-07-23 KR KR1020140093393A patent/KR101713103B1/ko active IP Right Grant
-
2015
- 2015-03-02 HK HK15102098.0A patent/HK1201536A1/zh not_active IP Right Cessation
- 2015-06-01 HK HK15105213.3A patent/HK1204623A1/xx unknown
- 2015-07-16 US US14/800,871 patent/US9597341B2/en active Active
-
2016
- 2016-07-18 CY CY20161100696T patent/CY1117834T1/el unknown
- 2016-09-20 HR HRP20161202TT patent/HRP20161202T8/hr unknown
- 2016-12-23 KR KR1020160177980A patent/KR20170001694A/ko not_active Application Discontinuation
-
2017
- 2017-02-06 US US15/425,119 patent/US20170143746A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24316B1 (es) | Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen | |
| CY1121744T1 (el) | Παραγωγα c4-μονομεθυλο-τριτερπενοειδους και μεθοδοι χρησης αυτων | |
| CY1121776T1 (el) | C17-αλκανοδιυλιο και παραγωγα αλκενοδιυλιου του ολεανολικου οξεος και μεθοδοι χρησης αυτων | |
| AR097158A1 (es) | Polimorfo de inhibidores de tirosina quinasa de bazo (syk) | |
| EA201690072A1 (ru) | Состав, содержащий гиполипидемическое средство | |
| RS52716B (en) | HYDROBENZAMIDE DERIVATIVES AS HEAT SHOCK PROTEIN INHIBITORS HSP90 | |
| JO3221B1 (ar) | مركبات حمض داي ميثيل - بنزويك مفيدة لعلاج الحالات الالتهابية | |
| EA201592144A1 (ru) | Производное фенола, способ его получения и его применение в медицине | |
| AR088551A1 (es) | Conjugados de hidromorfona con acido benzoico, derivados de acido benzoico y acido heteroarilcarboxilico; profarmacos, metodos de preparacion y uso de los mismos | |
| RS54526B1 (en) | USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS | |
| PH12015501752A1 (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors | |
| EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
| AR105494A1 (es) | Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido | |
| UY32004A (es) | Derivados de carbamatos de alquiltiazoles, su preparación y su aplicación en terapéutica | |
| BR112014004523A2 (pt) | composto e composição aromatizante | |
| AR074545A1 (es) | Proceso de preparacion de dihidroetorfina | |
| WO2014184272A3 (en) | Chemical compositions for targeting isocitrate dehydrogenase and for treating cancer | |
| AR081034A1 (es) | Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central | |
| ES2524086T3 (es) | Nuevo método para la preparación de ezetimiba | |
| NZ623265A (en) | Stilbenoid compounds as inhibitors for squamous carcinoma and hepatoma and uses thereof | |
| CR20210394A (es) | Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo | |
| CY1116477T1 (el) | Μεθοδος εnzυμatiκης συνθεσης toy (7s)-3,4-διμεθοξυδικυκλο[4.2.0] οκτα-1,3,5-τριενo-7-καρβοξυλικου οξεος ή εστερων αυτου και εφαρμογη στην συνθεση της ιβαμπραδινης και των αλατων αυτης | |
| EA201591487A1 (ru) | Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью | |
| AR082593A1 (es) | Proceso para la preparacion de pirazoles | |
| CY1120482T1 (el) | Μεθοδος συνθεσης 3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριενο-7-καρβονιτριλιου και εφαρμογη στη συνθεση της ιβαμπραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξy |